EA200500957A1 - Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний - Google Patents
Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеванийInfo
- Publication number
- EA200500957A1 EA200500957A1 EA200500957A EA200500957A EA200500957A1 EA 200500957 A1 EA200500957 A1 EA 200500957A1 EA 200500957 A EA200500957 A EA 200500957A EA 200500957 A EA200500957 A EA 200500957A EA 200500957 A1 EA200500957 A1 EA 200500957A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- prevention
- diseases
- dopa
- derivatives
- impaired
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001771 impaired effect Effects 0.000 abstract 6
- 208000028017 Psychotic disease Diseases 0.000 abstract 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 3
- 108010035075 Tyrosine decarboxylase Proteins 0.000 abstract 3
- 230000005540 biological transmission Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10261808A DE10261808A1 (de) | 2002-12-19 | 2002-12-19 | Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen |
PCT/DE2003/004204 WO2004056306A2 (de) | 2002-12-19 | 2003-12-18 | Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200500957A1 true EA200500957A1 (ru) | 2006-02-24 |
Family
ID=32478131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500957A EA200500957A1 (ru) | 2002-12-19 | 2003-12-18 | Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1615631A2 (es) |
JP (1) | JP2006511558A (es) |
CN (1) | CN1756542A (es) |
AU (1) | AU2003294664A1 (es) |
CA (1) | CA2513077A1 (es) |
DE (1) | DE10261808A1 (es) |
EA (1) | EA200500957A1 (es) |
MX (1) | MXPA05006409A (es) |
PL (1) | PL377524A1 (es) |
WO (1) | WO2004056306A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
PL1991522T3 (pl) * | 2006-02-17 | 2017-07-31 | Ratiopharm Gmbh | Deuterowane pochodne katecholaminy i leki zawierające te związki |
CN105078952A (zh) * | 2015-08-10 | 2015-11-25 | 中国康复研究中心 | 一种左旋多巴制剂及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52102431A (en) * | 1976-02-25 | 1977-08-27 | Kyowa Hakko Kogyo Co Ltd | Remedies for mental disorder |
IE47082B1 (en) * | 1977-07-01 | 1983-12-14 | Merrell Toraude & Co | -acetylenic amino acids |
US5149786A (en) * | 1989-10-12 | 1992-09-22 | Chiron Corporation | Dopamine releasing protein and antibody |
-
2002
- 2002-12-19 DE DE10261808A patent/DE10261808A1/de not_active Ceased
-
2003
- 2003-12-18 PL PL377524A patent/PL377524A1/pl not_active Application Discontinuation
- 2003-12-18 WO PCT/DE2003/004204 patent/WO2004056306A2/de not_active Application Discontinuation
- 2003-12-18 JP JP2004561055A patent/JP2006511558A/ja active Pending
- 2003-12-18 AU AU2003294664A patent/AU2003294664A1/en not_active Abandoned
- 2003-12-18 EP EP03785594A patent/EP1615631A2/de not_active Withdrawn
- 2003-12-18 CA CA002513077A patent/CA2513077A1/en not_active Abandoned
- 2003-12-18 CN CNA2003801066148A patent/CN1756542A/zh active Pending
- 2003-12-18 MX MXPA05006409A patent/MXPA05006409A/es unknown
- 2003-12-18 EA EA200500957A patent/EA200500957A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006511558A (ja) | 2006-04-06 |
CA2513077A1 (en) | 2004-07-08 |
EP1615631A2 (de) | 2006-01-18 |
WO2004056306A3 (de) | 2004-11-11 |
CN1756542A (zh) | 2006-04-05 |
PL377524A1 (pl) | 2006-02-06 |
WO2004056306A2 (de) | 2004-07-08 |
DE10261808A1 (de) | 2004-07-08 |
MXPA05006409A (es) | 2006-05-31 |
AU2003294664A1 (en) | 2004-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200801826A1 (ru) | Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения | |
EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
DK1317419T3 (da) | Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
ZA200305412B (en) | 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical. | |
EA200801492A1 (ru) | Фармацевтическое применение замещенных амидов | |
NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
EA200702498A1 (ru) | N-(пиридин-2-ил)сульфонамидные производные | |
EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
NO20022442L (no) | Legemidler for sykdommer i forbindelse med reduksjon i benmasse | |
RU2008127882A (ru) | Лечение пищевода барретта | |
BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
EA200401227A1 (ru) | Система доставки лекарства с контролируемым высвобождением, включающая правастатин | |
EA200401515A1 (ru) | Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
SE0102440D0 (sv) | New compound | |
EA200400707A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
EA200500958A1 (ru) | Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения | |
EA200500957A1 (ru) | Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний | |
NO20052562L (no) | Anvendelse av distrontiumsalter av 2-[N,N-di(karboksylmetyl)amino]-3-cyano-4-karboksylmetyl-tiofen-5-karboksylsyre for fremstilling av medikamenter for behandlingen av gastro-duodenal smerte. | |
SE0000303D0 (sv) | Novel compounds |